GPP
TRIB

Great Point Partners’s Trinity Biotech TRIB Stock Holding History

Great Point Partners’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,260
Closed -$4.11M – 33
2013
Q3 		$4.11M Buy
+1,260
New +$3.68M 2.85% 13

Other funds holding TRIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return

Great Point Partners's TRIB Position: Q4 2013 in Review

Great Point Partners sold out of Trinity Biotech (TRIB) in Q4 2013, closing a stake of 1,260 shares — an estimated $4.11M sold.

Great Point Partners first reported a position in TRIB in Q3 2013 and held it in 1 quarter. The position peaked at $4.11M in Q3 2013. 74 funds tracked by Wall St. Rank hold TRIB as of Q4 2013.

  • Great Point Partners reported no remaining Trinity Biotech position as of Q4 2013 after selling out during the quarter.
  • Great Point Partners sold 1,260 Trinity Biotech shares in Q4 2013, an estimated $4.11M.
  • Great Point Partners first reported a position in Trinity Biotech in Q3 2013 and held it in 1 quarter.
  • Great Point Partners's Trinity Biotech position peaked at $4.11M in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2013.

Based on Great Point Partners's 13F filing for Q4 2013, filed 14 Feb 2014.